Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe Sells 11,581 Shares

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CFO Oluyemi Okupe sold 11,581 shares of the stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $60.22, for a total value of $697,407.82. Following the completion of the sale, the chief financial officer now directly owns 113,816 shares of the company's stock, valued at $6,853,999.52. This represents a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Oluyemi Okupe also recently made the following trade(s):

• On Tuesday, April 15th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The stock was sold at an average price of $28.50, for a total value of $330,058.50.
• On Wednesday, April 2nd, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.26, for a total transaction of $338,860.06.

Hims & Hers Health Trading Down 3.6%

Shares of Hims & Hers Health stock traded down $2.30 during trading on Monday, hitting $62.35. The stock had a trading volume of 35,635,695 shares, compared to its average volume of 19,463,905. The business's 50-day moving average is $35.44 and its 200 day moving average is $33.90. The firm has a market cap of $13.96 billion, a price-to-earnings ratio of 141.71 and a beta of 1.84. Hims & Hers Health, Inc. has a 12 month low of $13.47 and a 12 month high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.08. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $586.01 million during the quarter, compared to analysts' expectations of $535.21 million. During the same quarter in the prior year, the company posted $0.05 EPS. The firm's revenue for the quarter was up 110.7% compared to the same quarter last year. As a group, equities analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Truist Financial cut their target price on shares of Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating on the stock in a research report on Thursday, April 10th. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. TD Cowen lowered Hims & Hers Health from a "buy" rating to a "hold" rating and dropped their price target for the stock from $44.00 to $30.00 in a research report on Tuesday, April 29th. Citigroup restated a "sell" rating and set a $30.00 target price (up from $25.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Finally, UBS Group reissued a "mixed" rating on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $37.67.

Institutional Trading of Hims & Hers Health

Hedge funds have recently bought and sold shares of the company. Farallon Capital Management LLC boosted its stake in shares of Hims & Hers Health by 64,338.5% in the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock worth $202,556,000 after acquiring an additional 8,364,000 shares during the period. Arrowstreet Capital Limited Partnership raised its position in shares of Hims & Hers Health by 192.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock valued at $152,436,000 after buying an additional 4,145,305 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Hims & Hers Health by 11.1% in the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock worth $489,817,000 after purchasing an additional 2,020,722 shares during the period. Nuveen LLC bought a new position in Hims & Hers Health during the first quarter valued at $58,403,000. Finally, Yong Rong HK Asset Management Ltd bought a new position in shares of Hims & Hers Health during the fourth quarter valued at approximately $41,104,000. Hedge funds and other institutional investors own 63.52% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.